Novartis (NVS) Stock Forecast & Price Target

Novartis logo
$155.20 -3.93 (-2.47%)
Closing price 03:59 PM Eastern
Extended Trading
$155.44 +0.24 (+0.15%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
3
Hold
9
Buy
6

Based on 18 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 3 have given a sell rating, 9 have given a hold rating, and 6 have given a buy rating for NVS.

Consensus Price Target

$152.25
-1.90% Downside
According to the 18 analysts' twelve-month price targets for Novartis, the average price target is $152.25. The highest price target for NVS is $180.00, while the lowest price target for NVS is $130.00. The average price target represents a forecasted downside of -1.90% from the current price of $155.20.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Analyst Ratings Over Time

TypeCurrent Forecast
11/18/25 to 11/18/26
1 Month Ago
10/19/25 to 10/19/26
3 Months Ago
8/20/25 to 8/20/26
1 Year Ago
11/18/24 to 11/18/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
Hold
9 Hold rating(s)
12 Hold rating(s)
8 Hold rating(s)
6 Hold rating(s)
Sell
3 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$152.25$145.60$141.20$122.33
Forecasted Upside-1.90% Downside-3.04% Downside-9.58% Downside-4.44% Downside
Consensus RatingHoldHoldHoldHold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisHealthcare CompaniesBroader Market
Consensus Rating Score
2.17
2.32
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside-1.90% Downside117.21% Upside16.84% Upside
News Sentiment Rating
Positive News

See Recent NVS News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/4/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 DowngradeBuy (B) ➝ Buy (B-)
10/30/2026
Deutsche Bank logo
Deutsche Bank
3 of 5 stars
DowngradeHold ➝ Sell
10/28/2026 Reiterated RatingSector Perform
10/28/2026 Reiterated RatingNeutral
10/28/2026Reiterated RatingOverweight$163.00+3.95%
10/28/2026 Initiated CoverageHold
9/21/2026 Reiterated RatingSell
9/11/2026 Lower TargetHold$147.00 ➝ $130.00-10.35%
9/10/2026UpgradeReduce ➝ Hold$123.00 ➝ $136.00-1.10%
9/8/2026 Reiterated RatingBuy
8/9/2026 Reiterated RatingBuy
7/23/2026 Reiterated RatingNeutral
7/22/2026 Reiterated RatingBuy
7/22/2026 Reiterated RatingNeutral
4/28/2026 Reiterated RatingSell ➝ Neutral
3/11/2026 UpgradeHold ➝ Buy$180.00+11.36%
2/17/2026 Reiterated RatingHold
12/23/2025 DowngradeSell
10/29/2025Set TargetHold$126.00+2.09%
10/27/2025 DowngradeNeutral
4/15/2025UpgradeStrong-Buy
11/19/2024 Reiterated RatingBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:35 PM ET.


Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 13, 2026. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Novartis AG:

  • Novartis AG recently demonstrated strong financial performance by beating analyst expectations in its most recent quarterly report, posting earnings per share of $2.46 against a consensus estimate of $2.25, which signals robust operational execution and profitability that can drive shareholder value.
  • The stock is currently trading at $160.59, a level that reflects a significant recovery from its fifty-two-week low of $123.24, indicating that the market is increasingly confident in the company's ability to sustain growth and deliver returns to investors.
  • Novartis AG offers a dividend yield of 1.92%, providing a steady stream of income for investors, which is particularly attractive in a volatile market environment as it helps offset potential price fluctuations and supports long-term wealth accumulation.
  • Institutional investors are showing renewed interest in the company, with Fisher Asset Management LLC increasing its position by 8.0% in the third quarter, suggesting that professional analysts and fund managers are recognizing the stock's potential and are willing to commit capital to it.
  • The company has a low beta of 0.40, meaning its stock price tends to be less volatile than the overall market, which can make it a stabilizing component in a diversified portfolio and reduce the risk of significant losses during market downturns.

Novartis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Novartis AG for these reasons:

  • The consensus rating from Wall Street analysts is "Hold" with an average price target of $152.25, which is below the current stock price of $160.59, suggesting that the stock may be overvalued relative to what analysts believe it is worth based on their fundamental analysis.
  • Novartis AG has a price-to-earnings ratio of 30.65, which is relatively high compared to many other pharmaceutical companies, indicating that investors are paying a premium for the company's earnings, which may limit the upside potential if growth does not accelerate as expected.
  • Short interest in the stock has been increasing in recent months, with the number of shares shorted rising to 4.5 million as of October 30, 2026, which suggests that some investors are betting against the stock and could put downward pressure on the price if they cover their positions.
  • The company's debt-to-equity ratio is 0.98, indicating that it has a significant amount of debt relative to its equity, which could limit its financial flexibility and increase its risk in the event of a downturn in the pharmaceutical industry or a rise in interest rates.
  • Novartis AG's revenue growth has been modest, with a year-over-year increase of only 4.4% in the most recent quarter, which may be insufficient to justify the current valuation and could lead to disappointment if the company fails to accelerate its growth rate in the future.

NVS Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $152.25, with a high forecast of $180.00 and a low forecast of $130.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted downside of -1.90% based on their 12-month stock forecasts.

Over the previous 90 days, Novartis's stock had 3 downgrades and 2 upgrades by analysts.

Novartis has been rated by research analysts at Bank of America, Berenberg Bank, Deutsche Bank, DZ Bank, HSBC, Morgan Stanley, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Novartis less than other "healthcare" companies. The consensus rating score for Novartis is 2.17 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how NVS compares to other companies.


MarketBeat monitors more than a dozen sources for Novartis analyst ratings, with the most recent rating issued on 11/4/2026.
From Our Partners